The combination of LTi-Exos and current screening methods based on AFP shows promise for the early detection of HCC
(A) ROC curve analysis was performed for early HCC (n = 95, 24 BCLC stage 0 HCC plus 71 BCLC stage A HCC) and healthy donors (n = 46) by estimating plasma exosomal Circ-CDYL expression.
(B) ROC curve analysis was performed for early HCC (n = 95) and healthy people (n = 46) by estimating the proportion of EpCAM+ exosomes.
(C) The proportion of EpCAM+ exosomes was estimated in the plasma of early HCC patients and healthy controls using flow cytometry assays.
(D) Pearson correlation analysis between exosomal Circ-CDYL expression and the proportion of EpCAM+ exosomes in the plasma of early HCC (n = 95).
(E) ROC curve analysis was performed for early HCC (n = 95) and healthy donors (n = 46) by combined EpCAM+ exosomes with exosomal Circ-CDYL estimating (LTi-Exos).
(F) AFP levels were estimated in the plasma of early HCC patients and healthy controls.
(G and H) ROC curve analysis was performed for early HCC patients (n = 95) and healthy donors (n = 46) by estimating the AFP level (G) and AFP combined with LTi-Exos (H).